

PATENT
224/090

compounds are more potent activators of a Retinoid X Receptor than of each and all of the Retinoic Acid Receptor isoforms α , β , and γ . This amendment is needed to clarify and remove any possible ambiguity that the specified compounds distinguish over the prior art compounds such as, e.g., 9-cis-retinoic acid discussed and shown on page 66 of the specification and the Maignon Ex. II compound discussed and shown on pages 70-71 of the specification.

Since the amendments to allowed claims 12 and 13 merely clarify and either narrow or do not change the scope of the claims, the amended claims are patentable and the proposed amendments require no additional search or examination.

Accordingly, entry of the proposed amendments to claims 12 and 13 is respectfully requested.

No fee is believed to be required by this communication. However, should any fee be required, the Assistant Commissioner is hereby authorized to charge any such fee to Deposit Account No. 12-2475.

Respectfully submitted,

LYON & LYON LLP

Dated: October 30, 1998

By: 

Hope E. Melville
Reg. No. 34,874

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600